- Home
- PFG vs MRNA Comparison
PFG vs MRNA Comparison
Compare PFG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFG
- MRNA
- Stock Information
- Founded
- PFG 1879
- MRNA 2010
- Country
- PFG United States
- MRNA United States
- Employees
- PFG N/A
- MRNA N/A
- Industry
- PFG Specialty Insurers
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFG Finance
- MRNA Health Care
- Exchange
- PFG Nasdaq
- MRNA Nasdaq
- Market Cap
- PFG 19.9B
- MRNA 16.5B
- IPO Year
- PFG N/A
- MRNA 2018
- Fundamental
- Price
- PFG $77.73
- MRNA $40.20
- Analyst Decision
- PFG Hold
- MRNA Hold
- Analyst Count
- PFG 14
- MRNA 18
- Target Price
- PFG $84.07
- MRNA $79.50
- AVG Volume (30 Days)
- PFG 1.2M
- MRNA 7.6M
- Earning Date
- PFG 02-10-2025
- MRNA 11-07-2024
- Dividend Yield
- PFG 3.78%
- MRNA N/A
- EPS Growth
- PFG N/A
- MRNA N/A
- EPS
- PFG N/A
- MRNA N/A
- Revenue
- PFG $14,066,500,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- PFG N/A
- MRNA N/A
- Revenue Next Year
- PFG $5.79
- MRNA N/A
- P/E Ratio
- PFG N/A
- MRNA N/A
- Revenue Growth
- PFG N/A
- MRNA N/A
- 52 Week Low
- PFG $72.21
- MRNA $35.80
- 52 Week High
- PFG $91.98
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- PFG 27.01
- MRNA 39.50
- Support Level
- PFG $77.17
- MRNA $41.06
- Resistance Level
- PFG $84.69
- MRNA $44.38
- Average True Range (ATR)
- PFG 1.26
- MRNA 2.43
- MACD
- PFG -0.69
- MRNA 0.29
- Stochastic Oscillator
- PFG 7.10
- MRNA 16.93
About PFG Principal Financial Group Inc
Principal Financial Group Inc is a leader in Global investment management offering businesses, individuals and institutional clients a wide range of financial products and services, including retirement, asset management and insurance through diverse family of financial services companies. It operates in four business segments that are Retirement and Income Solutions, Principal Global Investors, Principal International, and United States Insurance Solutions. The company receives maximum revenue in the form of premiums.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.